Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01208662 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
A Phase 3 study of Multiple Myeloma, sponsored by Paul Richardson, MD.
- Active
- Registry status
- Phase 3
- Development phase
- 729
- Enrollment target
- 20
- Study locations
NCT01208662: Active Phase 3 study of Multiple Myeloma, sponsored by Paul Richardson, MD.
NCT01208662 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by Paul Richardson, MD. The registered enrollment target is 729 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01208662, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Paul Richardson, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 729 participants
- Enrollment target
- 20
- Study locations
Study Summary
In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma. Specifically, the objective of this trial is to determine if, in the era of novel drugs, high dose therapy (HDT) is still necessary in the initial management of multiple myeloma in younger patients. In this study, HDT as compared to conventional dose treatment would be considered superior if it significantly prolongs progression-free survival by at least 9 months or more, recognizing that particular subgroups may benefit more compared to others.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Bortezomib
- PROCEDURE Autologous Stem Cell Transplant
Study Locations (20)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
- Cape Cod Healthcare - Hyannis
- Newton-Wellesley Hospital - Newton
California
- City of Hope - Duarte
- University of California at San Diego - La Jolla
- University of California, San Francisco - San Francisco
- Stanford University - Stanford
Florida
- University of Florida - Gainesville
- H. Lee Moffitt Cancer Center - Tampa
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Arizona Comprehensive Cancer Center - Tucson
Colorado
- Colorado Blood Cancer Institute - Denver
Georgia
- Emory University - Atlanta
Idaho
- Mountain States Tumor Institute at St. Luke's Regional Medical Center - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 729 participants |
| Start Date | 2010-09 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01208662
The ClinicalTrials.gov registry entry for NCT01208662 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 729 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (34% higher). The listed sponsor is Paul Richardson, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT01208662 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Massachusetts, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01208662 about?
NCT01208662 is a clinical study titled "Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65". In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma. Specifical...
What is the current status of trial NCT01208662?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 729 participants. The study started on 2010-09. Estimated completion is 2026-12.
What conditions does trial NCT01208662 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01208662?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Bortezomib (DRUG), Autologous Stem Cell Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT01208662?
This trial is sponsored by Paul Richardson, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01208662 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.